Known targets — ChEMBL curated mechanism
ACEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2BTKCACNA1CCACNA1DCACNA1FCACNA1SCCR5CPT1BCPT2DPP4DRD1DRD2EGFRERBB2ERBB4HRH1HRH3HTR1AHTR2AHTR2BHTR2CHTR4JAK1JAK2JAK3MPLMTORPPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PPARGSLC6A2SLC6A3SLC6A4SMOTYK2pol
The experimentally established mechanism targets of Maleic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Maleic Acid SCHEMBL8466867 | 1.00 | TSHR (0.90) | — | |
| Maleic Acid SCHEMBL3742398 | 0.95 | — | — | |
| Maleic Acid SCHEMBL29014432 | 0.95 | — | — | |
| Fumaric Acid SCHEMBL3998225 | 0.95 | — | — | |
| Fumaric Acid SCHEMBL615 | 0.95 | — | — | |
| Fumaric Acid SCHEMBL2046433 | 0.95 | TSHR (1.00) | — | |
| Maleic Acid SCHEMBL2046430 | 0.95 | TSHR (1.00) | — | |
| Maleic Acid SCHEMBL613 | 0.95 | — | — | |
| Maleic Acid SCHEMBL20487516 | 0.95 | TSHR (1.00) | — | |
| Fumaric Acid SCHEMBL6875 | 0.95 | TSHR (1.00) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019196955-A1 | HYDROPHILIC BERBERINE DERIVATIVE WITH R10 AND R11 CONNECTED AND APPLICATION THEREOF IN PREPARATION OF DRUGS | 中国医学科学院药物研究所 | 2019-10-17 | — | — | WO | claimed |
| WO-2019196957-A1 | HYDROPHILIC BERBERINE-TYPE DERIVATIVE AND APPLICATION THEREOF IN PREPARING DRUG | 中国医学科学院药物研究所 | 2019-10-17 | — | — | WO | claimed |
| CN-117500809-A | Novel 12-epimeric-mollin compounds and uses thereof | 纳布里瓦治疗有限责任公司 | 2024-02-02 | — | — | CN | disclosed |
| CN-109827984-B | Method for determining content of impurities or structural analogue reference substances in L-prolinamide synthesis process | 南京江北新区生物医药公共服务平台有限公司 | 2022-05-17 | — | — | CN | disclosed |
| EP-2614049-B1 | PLEUROMUTILIN DERIVATIVES FOR USE IN THE TREATMENT OF DISEASES MEDIATED BY MICROBES | Nabriva Therapeutics GmbH (AT) | 2018-02-28 | — | — | EP | disclosed |
| CN-105997969-A | Baclofen and Acamprosate based therapy of neurogical disorders | 法耐斯特公司 | 2016-10-12 | — | — | CN | disclosed |
| CN-103980258-B | Compounds as bradykinin B1 antagonists | 贝林格尔.英格海姆国际有限公司 | 2016-09-07 | — | — | CN | disclosed |
| US-9278920-B2 | Pleuromutilin derivatives for use in the treatment of diseases mediated by microbes | NABRIVA THERAPEUTICS AG (AT) | 2016-03-08 | — | — | US | disclosed |
| US-20130274329-A1 | PLEUROMUTILIN DERIVATIVES FOR USE IN THE TREATMENT OF DISEASES MEDIATED BY MICROBES | NABRIVA THERAPEUTICS AG (AT) | 2013-10-17 | — | — | US | disclosed |
| EP-2614049-A1 | PLEUROMUTILIN DERIVATIVES FOR USE IN THE TREATMENT OF DISEASES MEDIATED BY MICROBES | Nabriva Therapeutics AG (AT) | 2013-07-17 | — | — | EP | disclosed |
| EP-2433926-A1 | Pleuromutilin derivatives for use in the treatment of diseases mediated by microbes | Nabriva Therapeutics AG (AT) | 2012-03-28 | — | — | EP | disclosed |
| WO-2012031307-A1 | PLEUROMUTILIN DERIVATIVES FOR USE IN THE TREATMENT OF DISEASES MEDIATED BY MICROBES | NABRIVA THERAPEUTICS AG (AT) | 2012-03-15 | — | — | WO | disclosed |
| CN-1889833-A | Use of N-arylhydrazine derivatives for controlling pests in and on animals | BASF AG (DE) | 2007-01-03 | — | — | CN | disclosed |
| CN-1889832-A | Use of N-arylhydrazine derivatives for combating non-crop pests | BASF AG (DE) | 2007-01-03 | — | — | CN | disclosed |